Key Sponsors

We are delighted to announce the following companies/organisations/institutes as Sponsors of the XXV Biennial ISER Meeting 2023.



BrightFocus Foundation is a premier source of global research funding to defeat Alzheimer’s, macular degeneration, and glaucoma. The organization is the only nonprofit dedicated to finding cures for diseases of mind and sight and has supported nearly 2,000 projects since inception, a more than $275 million investment. BrightFocus shares the latest research findings and expert information to empower families impacted by these diseases.

Please visit  for more information on current grants and how to apply for future funding.


Our mission is “to improve vison through research, education, and supporting access to care.” The Foundation has learned over the years that our efforts in funding pediatric ophthalmology research have been the primary reason that we have had fewer and fewer children with strabismus (crossed eyes) to treat. Our research dollars have helped develop new, non-surgical treatments for this problem. The Foundation has grown to $162 million while expending $166 million on research, education, and patient care. The Foundation is continuing to invest into more research and the improvement of the quality of eye care not only here in the United States but around the world. The Foundation has awarded over $34 million in research grants and $10 million in endowments at five of the leading ophthalmology research and educational institutions.



As a global specialized company dedicated to eye health, Santen brings a more than 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceutical, surgical, and OTC eye care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen’s websites and (Japan headquarters).



AOPT is a global association of clinicians, academics, students, and industry professional members in the eye research and drug development fields. Our mission is the publication, dissemination, and exchange of information and knowledge in ocular pharmacology and therapeutic treatments of eye diseases. Members are invited to publish in the Journal of Ocular Pharmacology and Therapeutics, our flagship journal. The XVI Biennial meeting of AOPT will be an in-person/hybrid event hosted jointly in Indianapolis, (IN) and Shenyang, Liaoning Province (CH) in August 2023.
See our booth or website for membership, registration, dates to remember, submission templates, and requirements.


We are a global biopharmaceutical company leveraging courageous science, creativity and compassion to deliver life-changing medicines. As leaders in the research of targeted C3 therapies, we aim to develop new therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within haematology, nephrology, neurology and ophthalmology.



Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries worldwide. We are promoting the Focus Area Approach designed to identify opportunities for continuously creating new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Particularly, in Primary Focus Blindness and Regeneration, we are committed to developing transformative therapies to restore sight and free patients from the fear of deteriorating vision. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.


The University of Sydney

The Save Sight Institute (SSI) is home to many of Australia’s leading ophthalmologists, researchers, and scientists. SSI is one of six Flagship Centres in the Faculty of Medicine and Health at the University of Sydney. Established in 1985 and based at the Sydney Eye Hospital, SSI has grown to be one of the top two ophthalmic research institutes in Australia. SSI is internationally recognised as a centre of innovative research into clinical ophthalmology and vision science and is a centre of excellence for clinical research, learning and teaching.

Ophthalmology at the University of Sydney is ranked sixth in the world by the Centre for World University Rankings (CWUR, 2019). The centre currently has more than 70 substantive staff, 176 clinical affiliates and 14 higher degree research students. Research at the SSI encompasses four broad domains: basic vision science, research translation, clinical trials, and disease outcomes. Our cutting-edge laboratory research lays the foundation for our complementary work in clinical trials, implementation, and ongoing patient monitoring through our global outcome registry projects.



EyeCRO is the global leader in preclinical ophthalmic research specializing in studies of pharmacology/efficacy, PK/tox, and eyedrop formulation development.  Efficacy models include dry eye, allergic conjunctivitis, laser-induced choroidal neovascularization, STZ-induced diabetes, ischemia/reperfusion, inherited retinal degenerations, optic nerve crush, light-induced retinal degeneration, geographic atrophy, retinal vascular leakage, Oxygen-induced retinopathy, corneal neovascularization, glaucoma, experimental autoimmune uveitis, and LC-MS quantification of A2E.  Proprietary MiDROPS™ technology is also available to formulate small lipophilic molecules for topical instillation (eyedrop).  This patented technology platform can produce stable and safe formulations that deliver large amounts of drug into the eye.



Experimental Eye Research is the official journal of ISER and publishes research on all aspects of experimental biology of the eye and ocular tissues.



Striatech’s mission is to make innovative ideas and products from vision and behavioral research accessible to scientists worldwide.


Vision 20/20 Australia

Vision 2020 Australia is the national peak body for the eye health and vision care sector. Our vision is the elimination of preventable blindness and vision loss and the full participation of people who are blind and vision impaired in the community.It represents organisations involved in local and global eye health and vision care, health promotion, low vision support, vision rehabilitation, eye research, professional assistance and community support.



More information coming soon!


Contact us!

If you have further questions, please don’t hesitate to contact Industry Services at the official ISER Meeting Secretariat:

2023 ISER Meeting Secretariat
c/o K.I.T. Group GmbH
Industry Services

We look forward to hearing from you!